A personal care composition

Abstract

Disclosed is a personal care composition comprising carboxymethyl cysteine compound and unsubstituted fatty acid, wherein the molar ratio of the carboxymethyl cysteine compound to the unsubstituted fatty acid is at least 2.5:1.

Description

[0001] P0000953W01 CPL

[0002] 1

[0003] A PERSONAL CARE COMPOSITION

[0004] Field of the Invention

[0005] The present invention relates to a personal care composition comprising carboxymethyl

[0006] 5 cysteine compound and unsubstituted fatty acid, wherein the molar ratio of the carboxymethyl cysteine compound to the unsubstituted fatty acid is at least 2.5:1. It was unexpectedly found that such composition is capable of significantly inhibiting reactive oxygen species.

[0007] Background of the Invention

[0008] Human skin may provide physicochemical protection against environmental insults through its barrier function, mechanical strength and imperviousness to water. It is constantly exposed to harmful environments and extreme conditions, such as ultra-violet radiation, blue light, pollution, and etc. Such harmful environmental applications may cause excessive generation of reactive oxygen species (ROS) thereby resulting in an oxidative stress condition. Oxidative stress may

[0009] 15 affect our skin in many ways including signs of premature aging such as wrinkles, fine lines, uneven skin tone.

[0010] Therefore, a lot of efforts have been made for developing personal care composition for preventing excessive generation of reactive oxygen species, but improvements still will be

[0011] 20 required.

[0012] Therefore, the present inventors have recognized there is a need to further develop a personal care composition which is able to effectively inhibit the generation of reactive oxygen species. It was surprisingly found that a combination of carboxymethyl cysteine compound with

[0013] 25 unsubstituted fatty acid in a specific ratio exhibits a significantly better effect for inhibiting reactive oxygen species.

[0014] Summary of the Invention

[0015] In a first aspect, the present invention is directed to a personal care composition comprising carboxymethyl cysteine compound and unsubstituted fatty acid, wherein the molar ratio of the carboxymethyl cysteine compound to the unsubstituted fatty acid is at least 2.5:1.

[0016] In a second aspect, the present invention is directed to a method for providing at least one benefit selected from anti-aging, antioxidant, or oxidative stress reduction comprising a step of

[0017] 35 applying the personal care composition of the present invention. P0000953W01 CPL

[0018] 2

[0019] In a third aspect, the present invention is directed to use of a personal care composition of the present invention for at least one benefit selected from anti-aging, antioxidant, or oxidative stress reduction.

[0020] 5

[0021] All other aspects of the present invention will more readily become apparent upon considering the detailed description and examples which follow.

[0022] Detailed Description of the Invention

[0023] Except in the examples, or where otherwise explicitly indicated, all numbers in this description indicating amounts of material or conditions of reaction, physical properties of materials and / or use may optionally be understood as modified by the word “about”.

[0024] All amounts are by weight of the composition, unless otherwise specified.

[0025] 15

[0026] It should be noted that in specifying any range of values, any particular upper value can be associated with any particular lower value.

[0027] For the avoidance of doubt, the word “comprising” is intended to mean “including” but not

[0028] 20 necessarily “consisting of” or “composed of’. In other words, the listed steps or options need not be exhaustive.

[0029] The disclosure of the invention as found herein is to be considered to cover all embodiments as found in the claims as being multiply dependent upon each other irrespective of the fact that

[0030] 25 claims may be found without multiple dependency or redundancy.

[0031] Where a feature is disclosed with respect to a particular aspect of the invention (for example a composition of the invention), such disclosure is also to be considered to apply to any other aspect of the invention (for example a method of the invention) mutatis mutandis.

[0032] The carboxymethyl cysteine compound refers to compound selected from carboxymethyl cysteine, salt of carboxymethyl cysteine, ester of carboxymethyl cysteine, amide of carboxymethyl cysteine or a mixture thereof. Preferably, the carboxymethyl cysteine compound comprises carboxymethyl cysteine, ester of carboxymethyl cysteine, and / or salt of

[0033] 35 carboxymethyl cysteine. More preferably, the carboxymethyl cysteine compound comprises P0000953W01 CPL

[0034] 3 carboxymethyl cysteine, and / or salt of carboxymethyl cysteine. Even more preferably, carboxymethyl cysteine compound comprises salt of carboxymethyl cysteine. Still even more preferably the carboxymethyl cysteine compound comprises lysine carboxymethyl cysteinate and most preferably, the carboxymethyl cysteine compound is lysine carboxymethyl cysteinate.

[0035] 5

[0036] Preferably, the carboxymethyl cysteine compound is present in amount of at least 0.00001%, more preferably at least 0.0001 %, even more preferably at least 0.001%, still even more preferably at least 0.01 %, and most preferably at least 0.1% by weight of the composition.

[0037] Preferably, the carboxymethyl cysteine compound is present in amount of no greater than 10%, more preferably no greater than 5%, even more preferably no greater than 3%, still even more preferably no greater than 1%, and most preferably no greater than 0.5% by weight of the composition.

[0038] Preferably, the lysine carboxymethyl cysteinate is present in amount of no greater than 10%,

[0039] 15 more preferably no greater than 5%, even more preferably no greater than 3%, still even more preferably no greater than 1%, and most preferably no greater than 0.5% by weight of the composition. Preferably, the lysine carboxymethyl cysteinate is present in amount of at least 0.00001%, more preferably at least 0.0001 %, even more preferably at least 0.001%, still even more preferably at least 0.01 %, and most preferably at least 0.1 % by weight of the composition.

[0040] 20

[0041] The term unsubstituted for unsubstituted fatty acid typically means the fatty acid radical is free from substituent groups such as OH, Cl or amino. Fatty acid as used herein refers to carboxylic acids with an aliphatic chain of at least 6 carbon atoms, preferably 6 to 30 carbon atoms. The unsubstituted fatty acid can be branched or unbranched, preferably unbranched unsubstituted

[0042] 25 fatty acids. Preferably, the unsubstituted fatty acid comprises a straight chain having at least 4, more preferably straight chain having at least 6 carbon atoms, even more preferably a straight chain having 8 to 30 carbon atoms, still even more preferably straight chain having 10 to 26 carbon atoms and most preferably straight chain having 12 to 24 carbon atoms.

[0043] 30 Preferably, the unsubstituted fatty acid is C8-C24 unsubstituted fatty acid, more preferably unsubstituted C10-C22 fatty acid, even more preferably unsubstituted C14-C20 fatty acid and still even more preferably unsubstituted C16-C18 fatty acid. Preferably, the unsubstituted fatty acid is saturated. Preferably, the unsubstituted fatty acid is selected from myristic acid, palmitic acid and stearic acid. More preferably, Preferably, the unsubstituted fatty acid is palmitic acid. P0000953W01 CPL

[0044] 4

[0045] For sake of clarity, the unsubstituted fatty acid also includes salt of the unsubstituted fatty acid, especially sodium salt thereof but preferably, the unsubstituted fatty acid is free unsubstituted fatty acid.

[0046] 5 The amount of unsubstituted fatty acid in the composition is preferably from 0.000001 to 25% by weight of the composition, more preferably from 0.00001 to 7%, even more preferably from 0.0001 to 4%, still even more preferably from 0.001 to 2% and most preferably from 0.05 to 0.6% by weight of the composition.

[0047] Preferably, the molar ratio of the carboxymethyl cysteine compound to the unsubstituted fatty acid is 2.5:1 to 200:1, more preferably 2.5:1 to 60:1, even more preferably 2.5:1 to 20:1, and still even more preferably 3:1 to 7:1.

[0048] Preferably, the personal care composition comprising carboxymethyl cysteine compound and

[0049] 15 C8-C24 unsubstituted fatty acid, wherein the molar ratio of the carboxymethyl cysteine compound to the C8-C24 unsubstituted fatty acid is at least 2.5:1. The amount of C8-C24 unsubstituted fatty acid in the composition is preferably from 0.000001 to 25% by weight of the composition, more preferably from 0.00001 to 7%, even more preferably from 0.0001 to 4%, still even more preferably from 0.001 to 2% and most preferably from 0.05 to 0.6% by weight of the

[0050] 20 composition. Preferably, the molar ratio of the carboxymethyl cysteine compound to the C8-C24 unsubstituted fatty acid is 2.5:1 to 200:1 , more preferably 2.5:1 to 60:1 , even more preferably 2.5:1 to 20:1, and still even more preferably 3:1 to 7:1.

[0051] More preferably, the personal care composition comprising carboxymethyl cysteine compound

[0052] 25 and C14-C20 unsubstituted fatty acid, wherein the molar ratio of the carboxymethyl cysteine compound to the C14-C20 unsubstituted fatty acid is at least 2.5:1. The amount of C14-C20 unsubstituted fatty acid in the composition is preferably from 0.000001 to 25% by weight of the composition, more preferably from 0.00001 to 7%, even more preferably from 0.0001 to 4%, still even more preferably from 0.001 to 2% and most preferably from 0.05 to 0.6% by weight of the composition. Preferably, the molar ratio of the carboxymethyl cysteine compound to the C14-C20 unsubstituted fatty acid is 2.5:1 to 200:1 , more preferably 2.5:1 to 60:1 , even more preferably 2.5:1 to 20:1, and still even more preferably 3:1 to 7:1.

[0053] Even more preferably, the personal care composition comprising lysine carboxymethyl

[0054] 35 cysteinate and C14-C20 unsubstituted fatty acid, wherein the molar ratio of the lysine P0000953W01 CPL

[0055] 5 carboxymethyl cysteinate to the C14-C20 unsubstituted fatty acid is at least 2.5:1. The amount of C14-C20 unsubstituted fatty acid in the composition is preferably from 0.000001 to 25% by weight of the composition, more preferably from 0.00001 to 7%, even more preferably from 0.0001 to 4%, still even more preferably from 0.001 to 2% and most preferably from 0.05 to 0.6% by

[0056] 5 weight of the composition. Preferably, the molar ratio of the lysine carboxymethyl cysteinate to the C14-C20 unsubstituted fatty acid is 2.5:1 to 200:1 , more preferably 2.5:1 to 60:1 , even more preferably 2.5:1 to 20:1 , and still even more preferably 3:1 to 7:1.

[0057] Still even more preferably, the personal care composition comprising lysine carboxymethyl cysteinate and palmitic acid, wherein the molar ratio of the lysine carboxymethyl cysteinate to the palmitic acid is at least 2.5:1 . The amount of palmitic acid in the composition is preferably from 0.000001 to 25% by weight of the composition, more preferably from 0.00001 to 7%, even more preferably from 0.0001 to 4%, still even more preferably from 0.001 to 2% and most preferably from 0.05 to 0.6% by weight of the composition. Preferably, the molar ratio of the

[0058] 15 lysine carboxymethyl cysteinate to the palmitic acid is 2.5:1 to 200:1 , more preferably 2.5:1 to 60: 1 , even more preferably 2.5: 1 to 20: 1 , and still even more preferably 3:1 to 8: 1 .

[0059] Preferably, the composition comprises Vitamin B3 compounds (including derivatives of vitamin B3). The vitamin B3 compounds comprises niacin, nicotinic acid, niacinamide or a mixture

[0060] 20 thereof. The most preferred vitamin B3 compound is niacinamide. Amount of Vitamin B3 compounds may be 0.1 to 10%, preferably 0.5 to 5% by weight of the composition.

[0061] Preferably, the composition comprises a glutamate source selected from the group consisting of glutamine, glutamine ester, glutamic acid, pyroglutamic acid, salts, and mixtures thereof. More

[0062] 25 preferably, the composition comprises pyroglutamic acid and / or salt of pyroglutamic acid. Even more preferably, the composition comprises sodium salt of pyroglutamic acid. Preferably, the glutamate source is present in amount of 0.0001 to 10% by weight of the composition, more preferably 0.001 to 6%, even more preferably 0.01 to 3% by weight of the composition.

[0063] The composition may optionally comprise whitening pigment. Whitening pigments are typically particles of high refractive index materials. For example, the whitening pigment may have a refractive index of greater than 1.3, more preferably greater than 1.8 and most preferably from 2.0 to 2.7. Examples of such whitening pigment are those comprising bismuth oxy-chloride, boron nitride, barium sulfate, mica, silica, titanium dioxide, zirconium oxide, aluminium oxide,

[0064] 35 zinc oxide or combinations thereof. More preferred whitening pigment are particles comprising P0000953W01 CPL

[0065] 6 titanium dioxide, zinc oxide, zirconium oxide, mica, iron oxide or a combination thereof. Even more preferred whitening pigment are particles comprising zinc oxide, zirconium oxide, titanium dioxide or a combination thereof as these materials have especially high refractive index. Still even more preferably the whitening pigment is selected from titanium dioxide, zinc oxide or a

[0066] 5 mixture thereof and most preferred whitening pigment is titanium dioxide. The average diameter of whitening pigment is typical from 15 nm to 1 micron, more preferably from 35 nm to 800 nm, even more preferably from 50 nm to 500 nm and still even more preferably from 100 to 300 nm. Amount of whitening pigment may be 0.1 to 15%, preferably 0.5 to 5% by weight of the composition.

[0067] Preferably, the composition comprises a glutamate source selected from the group consisting of glutamine, glutamine ester, glutamic acid, pyroglutamic acid, salts, and mixtures thereof. More preferably, the composition comprises pyroglutamic acid and / or salt of pyroglutamic acid. Even more preferably, the composition comprises sodium salt of pyroglutamic acid. Preferably, the

[0068] 15 glutamate source is present in amount of 0.0001 to 10% by weight of the composition, more preferably 0.001 to 6%, even more preferably 0.01 to 3% by weight of the composition.

[0069] Preferably, the composition comprises polyhydric alcohol. Polyhydric alcohols may be selected from group of glycerin, propylyene glycol, dipropylene glycol, polypropylene glycol, polyethylene

[0070] 20 glycol, sorbitol, hydroxypropyl sorbitol, hexylene glycol, 1,3-butylene glycol, isoprene glycol, ethoxylated glycerol, propoxylated glycerol or a mixture thereof. Most preferred polyhydric alcohol is glycerol known also as glycerin. The amount of polyhydric alcohol may range anywhere from 0.1 to 20%, preferably 0.5 to 15% and more preferably 2 and 10% by weight of the composition.

[0071] 25

[0072] Preferably, the composition comprises emollient materials. Suitable emollient materials include silicones, hydrocarbons, triglycerides or a mixture thereof. These silicones may be organic, silicone-containing or fluorine-containing, volatile or non-volatile, polar or non-polar.

[0073] Hydrocarbons may include mineral oil, petrolatum and polyalpha-olefins. Examples of preferred volatile hydrocarbons include polydecanes such as isododecane and isodecane (e.g. Permethyl-99A which is available from Presperse Inc.) and the C7-C8 through C12-C15 isoparaffins (such as the Isopar Series available from Exxon Chemicals). Illustrative triglycerides but not limiting are sunflower seed oil, cotton oil, canola oil, soybean oil, castor oil, borage oil, olive oil, shea butter, jojoba oil and mixtures thereof. Mono- and di- glycerides may

[0074] 35 also be useful. Particularly preferable are glyceryl monostearate and glyceryl distearate. P0000953W01 CPL

[0075] 7

[0076] Preferably, the composition comprises moisturizing agents. Particularly preferred moisturizing agents includes, petrolatum, aquaporin manipulating actives, oat kernel flour, substituted urea like hydroxyethyl urea, hyaluronic acid and / or its precursor N-acetyl glucosamine, hyaluronic

[0077] 5 acid and / or its precursor N-acetyl glucosamine, or a mixture thereof.

[0078] Some compositions may include thickeners. These may be selected from cellulosics, natural gums and acrylic polymers but not limited by this thickening agent types. Among the cellulosics are sodium carboxymethyl cellulose, hydroxyethyl cellulose, hydroxypropyl methylcellulose and combinations thereof. Suitable gums include xanthan, pectin, karaya, agar, alginate gums and combinations thereof. Among the acrylic thickeners are homopolymers and copolymers of acrylic and methacrylic acids including carbomers such as Carbopol 1382, Carbopol 982, llltrez, Aqua SF-1 and Aqua SF-2 available from the Lubrizol Corporation. Amounts of thickener may range from 0.01 to 3% by weight of the active polymer (outside of solvent or water) in the

[0079] 15 compositions.

[0080] In addition, the compositions of the invention may further include 0.5 to 10% by weight of sequestering agents, such as tetra sodium ethylenediaminetetraacetate (EDTA), EHDP or mixtures; opacifiers and pearlizers such as ethylene glycol distearate, titanium dioxide or Lytron

[0081] 20 621 (Styrene / Acrylate copolymer); all of which are useful in enhancing the appearance or properties of the product.

[0082] The composition may comprise water in amount of 10 to 96% by weight of the composition, more preferably from 25 to 92%, even more preferably from 42 to 88%, most preferably from 55

[0083] 25 to 82% by weight of the composition.

[0084] Preferably, the composition has a viscosity of at least 10 mPa s, more preferably in the range 30 to 10000 mPa s, even more preferably 50 to 5000 mPa s, and most preferably 100 to 2000 mPa s, when measured at 20 degrees C at a relatively high shear rate of about 20 s'1.

[0085] Preferably, the composition is an emulsion, more preferably an oil-in-water emulsion. Preferably the composition is a fluid liquid at 25 °C and atmospheric pressure.

[0086] Preferably, the personal care composition is a skin care composition. Skin care composition

[0087] 35 refers to a composition suitable for topical application to human skin, including leave-on and P0000953W01 CPL

[0088] 8 wash-off products but preferably leave-on compositions. The term “leave-on” as used with reference to compositions herein means a composition that is applied to or rubbed on the skin, and left thereon. The term “wash-off” as used with reference to compositions herein means a skin cleanser that is applied to or rubbed on the skin and rinsed off substantially immediately

[0089] 5 subsequent to application. The term "skin" as used herein includes the skin on the face, neck, chest, abdomen, back, arms, under arms, hands, and legs. Preferably “skin” means includes the skin on the face and under arms, more preferably skin means skin on the face other than lips and eyelids. The composition is particularly preferably a moisturizer rather than a make-up product.

[0090] Preferably, the composition is a topical composition. Preferably, the composition may be in the form of cream, lotion, ointment, solution, suspension, emulsion, paste, gel, powder, powder foundation, emulsion foundation, wax foundation, or spray. More preferably, the composition may be formulated in the form of cream, lotion, ointment, emulsion, gel, or a spray.

[0091] 15

[0092] Preferably, the composition is capable of inhibiting reactive oxygen species by at least 10 to 90% more preferably 30 to 70%, and even more preferably 40 to 65%, typically in comparison to personal care composition comprising neither carboxymethyl cysteine compound nor unsubstituted fatty acid.

[0093] 20

[0094] Preferably the use is non-therapeutic. Preferably the method is non-therapeutic. The term non- therapeutic typically means for cosmetic purposes and not curative or therapeutic purposes.

[0095] The following examples are provided to facilitate an understanding of the invention. The

[0096] 25 examples are not intended to limit the scope of the claims.

[0097] Examples

[0098] Example 1

[0099] This Example demonstrates inhibition of reactive oxygen species by the composition of the present invention.

[0100] Normal Human Epidermal Keratinocytes (NHEKs) (Biocell, Xi’an, China) were cultured in keratinocyte culture medium and plated in 6-well plates. On the second day, the culture medium

[0101] 35 was replaced with medium containing the test samples. P0000953W01 CPL

[0102] The moringa oil was dissolved in DMSO (dimethyl sulfoxide) at a concentration of 100 mM to form a stock solution. The samples in Table 1 were prepared accordingly by diluting the materials (except moringa oil) and / or stock solution with PBS (phosphate-buffered saline) to the

[0103] 5 desired levels as indicated in Table 1 before use for further experiment.

[0104] After incubation in each sample for another 24 hours, the medium was replaced with PBS. The cells were then irradiated with blue light using a blue LED (PL-L 18 W / 52 / 4P, Philips, Poland), which emits light almost entirely within the 400 to 500 nm bandwidth and peaks at 450 nm. The

[0105] 10 radiation of the LED was measured with a Blue Light Safety Detector (PMA2121) (SolarLight, PA, USA) and the total energy for the blue light irradiation is 10 J / cm2. The ROS (reactive oxygen species) production was evaluated after irradiation by blue light for 30 minutes, using the DCFH-DA (2',7'-Dichlorodihydrofluorescein diacetate) dye and detected with flowcytometry (CytoFLEX, Beckman Coulter, USA). Data was acquired and analyzed using the CytExpert programme (Beckman Coulter, USA).

[0106] The results were summarised in Table 1.

[0107] Table 1

[0108] 20 *The level refers to the level of the listed ingredient based on the medium. a: LCC: Lysine carboxymethyl cysteinate, Hair App procured from Sinerga. b: not significantly better than at least one sample containing single active (p<0.05, E vs. A or D). c: significantly better than both samples containing single active (p<0.05, 1 vs. B or D; 2 vs. C or D).

[0109] 25

[0110] It is evident from the data in Table 1 that the reactive oxygen species inhibition was significantly better when combining lysine carboxymethyl cysteinate and palmitic acid in a molar ratio of the present invention.

Claims

P0000953W01 CPL10Claims1. A personal care composition comprising carboxymethyl cysteine compound and unsubstituted fatty acid, wherein the molar ratio of the carboxymethyl cysteine compound to the unsubstituted fatty acid is at least 2.5:1 , and the composition comprises water in amount of 10 to 96% by weight of the composition.

2. The composition according to claim 1 wherein the carboxymethyl cysteine compound comprises carboxymethyl cysteine, ester of carboxymethyl cysteine, and / or salt of carboxymethyl cysteine.

3. The composition according to claim 2 wherein the carboxymethyl cysteine compound comprises salt of carboxymethyl cysteine and preferably the carboxymethyl cysteine compound comprises lysine carboxymethyl cysteinate.

4. The composition according to any one of the preceding claims wherein the carboxymethyl cysteine compound is present in amount of at least 0.00001% and no greater than 10% by weight of the composition, preferably carboxymethyl cysteine compound is present in amount of at least 0.01 % and no greater than 3% by weight of the composition.

5. The composition according to any one of the preceding claims wherein the unsubstituted fatty acid is saturated.

6. The composition according to any one of the preceding claims wherein the unsubstituted fatty acid is C8-C24 unsubstituted fatty acid, preferably the unsubstituted fatty acid is unsubstituted C14-C20 fatty acid, more preferably the unsubstituted fatty acid is palmitic acid.

7. The composition according to any one of the preceding claims wherein the amount of unsubstituted fatty acid in the composition is preferably from 0.000001 to 25% by weight of the composition, preferably from 0.0001 to 4% by weight of the composition.

8. The composition according to any one of the preceding claims wherein the molar ratio of the carboxymethyl cysteine compound to the unsubstituted fatty acid is 2.5:1 to 200:1 , preferably 3:1 to 8:1.P0000953W01 CPL119. The composition according to any one of the preceding claims wherein the composition is an emulsion, preferably an oil-in-water emulsion.

10. The composition according to any one of the preceding claims wherein the composition is a fluid liquid at 25 °C and atmospheric pressure.

11. The composition according to any one of the preceding claims wherein the composition comprises water in amount of from 42 to 88% by weight of the composition.

12. A method for providing at least one benefit selected from anti-aging, antioxidant, or oxidative stress reduction comprising a step of applying the personal care composition of any one of claims 1 to 11.

13. Use of a personal care composition of the present invention for at least one benefit selected from anti-aging, antioxidant, or oxidative stress reduction of any one of claims 1 to 11.

Images